Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 11 Publications

3 Customer Reviews

  • Immunofluorescence staining of LC3 protein expression of U2OS cells treated with DMSO (negative control), Rap (positive control, 500 nM), Tha (1 μM), Tun (2 μg/mL), BFA (10 μg/mL), and DTT (4 mM) for 8 h. Immunoblot of ER-phagy-related proteins of U2OS cells treated with four ER stress inducers.

    Nanoscale, 2018, 10(18):8796-8805. Brefeldin A purchased from Selleck.

    Cells were treated with brefeldin A or manumycin A, and the resulting supernatant was collected after 48 h for exosomal preparation (lanes 1 and 2), or exosomes obtained from C81 cells were trypsin-treated or freeze/thawed (F/T) and then trypsin-treated (lanes 3 and 4). Lanes 5 and 6, input exosome controls from C81 or CEM cells, respectively. Resulting exosomes were assayed for the presence of Tax by Western blotting.

    J Biol Chem, 2014, 289(32):22284-305.. Brefeldin A purchased from Selleck.

  • CSFV proliferation in ST cells with or without BFA was observed by IFA at 24, 48 and 72 hpi.

    J Biosci, 2018, 42(1):43-56. Brefeldin A purchased from Selleck.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5] Brefeldin A could improve the HDR(homology-directed repair) efficiency. It is an enhancer of CRISPR-mediated HDR[6].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 NFnhbWRHfW6ldHnvckBCe3OjeR?= NHjNdWIzKM7:TR?= Ml3lNUBp NXjVW4VFcW6qaXLpeJMhfGinIFytSG9RSSBqMkFCpO69VSlvaX7keYNm\CC2cnHud4lmdnRiRWLLNU8zKHCqb4PwbI9zgWyjdHnvcuKh MojPNlY{PjNzOUG=
C2C12 NFfZUXlHfW6ldHnvckBCe3OjeR?= Mn73NeKh|rypL33s NGrMOlAyyqCq MXfhZo9tcXOqZYOgZ5l1d2urbnWgdoVt\WG|ZTDmdo9uKEN{Q{GyJI16d3S3YnXz MXeyOlI6OTJ5OR?=
MEFs WT NFjOe|JHfW6ldHnvckBCe3OjeR?= NEO0NZM2yqEQvF2= M2XIOFIxKG2rbh?= MlT6Z4F2e2W|IILld4ll\W62IHXufplu\XNic4XjbEBieyCQQVfUMWdHWCxidH:g[Iln\nW|ZTDiZYNsKHSxIITo[UBGWg>? M2\aRVI3OTl4MEKz
MEFs VAMP7 KO NGTqWmhHfW6ldHnvckBCe3OjeR?= M3PwclXDqM7:TR?= MXeyNEBucW5? NH\I[mhk[XW|ZYOgdoV{cWSnboSg[Y57gW2nczDzeYNpKGG|IF7BS3QuT0[SLDD0c{BlcW[odYPlJIJi[2tidH:geIhmKEWU NELmUoUzPjF7NkCyNy=>
SMCs M3PhRWZ2dmO2aX;uJGF{e2G7 NGC5TowyOMLiwsXnM41t NEnsXXYxNTF{IHi= MYrEUXNQ NInVeYl{cG:5czDhJJRz\W6mIITve4Fz\HNiYTDobYdp\XJiY3;uZ4VvfHKjdHnvckBw\iC2aHWgSXIwW1JibnX0e49zcyCrbjD0bIUheGW{aX71Z4xm[XJiYYLlZeKh NG\JUYYzPjF5MkC4NC=>
SMCs NIXNZVFHfW6ldHnvckBCe3OjeR?= M335fFExyqEEtXevcYw> MXuwMVEzKGh? MnnYSG1UVw>? NU[4OWd1[2G3c3XzJIEhfHKjboPp[Y51KEOjMjxCpJJmdGWjc3Wg[pJwdSC2aHWgSXIwW1MEoB?= MVmyOlE4OjB6MB?=
HEMC-1 NWX6N2R5TnWwY4Tpc44hSXO|YYm= NYPvTlhLOC5zwrFCuYcwdWx? Mkn1NlTDqGh? NHLBb2dk[XW|ZYOgZUBpcWeqZYKgbY5pcWKrdH;yfUBm\m[nY4Sgc44h\XixY4n0c5NqeyC2aHHuJI5w[2:mYYrvcIU> NFPhWlAzPTl5Mke1PS=>
HUVEC NVTsemp1TnWwY4Tpc44hSXO|YYm= Mn\PNVDDqM7:TR?= Ml3PNeKhcA>? NYD1TpVOTE2VTx?= NVftb2hu[WKxbHnzbIV{KGi7cH;4bYEucW6mdXPl[EBz\WynYYPlJI9nKEGWUDDmdo9uKGGyaXPhcEBidmRiYnHzc4xifGW{YXygd5Vz\mGlZYO= NGr1UWkzPTl3Nkm4PC=>
HUVEC NUf6OJRtTnWwY4Tpc44hSXO|YYm= M{DzTFExyqEQvF2= NWDJ[ZBLOcLiaB?= M{DUSGROW09? M{fjZYlv[3KnYYPld:KhfGinIH71cYJmeiCjbnSgbY51\W6|aYT5JI9nKG[udX;y[ZNk\W62IHHy[YF{KGW|cHXjbYFtdHliaX6gdIVzcW63Y3zlZZIhe3CjY3W= M3zMOVI2QTV4OUi4
Caco-2 M{Li[GZ2dmO2aX;uJGF{e2G7 MXeyMlUh|ryP M{j5UFMxKG2rbh?= MXvheJRmdnWjdHXzJJRp\SCWR1[t{tIyNW2nZHnheIVlKGmwY4LlZZNmKGmwIGPFVnQh\nWwY4Tpc44> MoW2NlU6PTR7M{G=
NRK NHzCWlRHfW6ldHnvckBCe3OjeR?= M3fjeFIxOOLChX7nM41t M4TuWlTjiIWq NXvjSJhkTE2VTx?= NYH0XFJkemW|Y4Xld{BucXSxdHnjJJBzd2e{ZYPzbY9v M3\YOFI2QTR6NUi2
HeLa NWrrVohUTnWwY4Tpc44hSXO|YYm= NEXYSpUzODEkgJXu[{9udA>? NWXMfIdlOyCq MX7EUXNQ MYLpcoR2[2W|IITo[UBienSrZnnjbYFtKGK{ZXHrMZVxKG:oIITo[UBId2ypaTDjc41xdGW6 NGjpOGMzPTl2OEW4Oi=>
COS M{LXWGZ2dmO2aX;uJGF{e2G7 MWOxJO69\y:vbB?= NIiwc3A{KGh? MVzjc41xdGW2ZXz5JIRqe3CncoPld{B1cGViQWCtNUB{cWewYX|CpC=> Mo[xNlU6OTV7MEC=
DF1  NHjLUXdHfW6ldHnvckBCe3OjeR?= NGn0T5QyyqEQvF5CpC=> NF7BS3o1QCCq MXPEUXNQ MlnY[Il{eGW{c3XzxsB1cGViZYjv[4Vvd3W|IFPTS4FtVkGlVEKgdJJwfGWrbh?= MoHkNlU5ODdyNUS=
nHDFs  M4[3emZ2dmO2aX;uJGF{e2G7 NGLWPJoyyqEQvF5CpC=> NEjPWZUzyqCq M3zJ[ZBz\X[nboTzJJRp\SCjc4PlcYJtgSCxZjDjfZRwe2:uaXOgZ49ifCCycn;0[YlveyCxboTvJGdwdGerIH3lcYJz[W6ncx?= M2fCfVI2Pzd{NkG2
FRT  NF\lfYpHfW6ldHnvckBCe3OjeR?= MljxOUDPxGdxbXy= NVvvVHR7OsLiaB?= NFrrRm9jdG:la4OgeJJi\m[rY3vpcochfGi{b4XnbEB1cGViR3;s[4kh[2:vcHzlfEBjgSCrbnjpZol1cW6pIFXSMZRwNUexbHfpJJRz[W6|cH;yeC=> NI\0cpMzPTd4N{GxOS=>
FRT  NWnMeHNHTnWwY4Tpc44hSXO|YYm= MknmOUDPxGdxbXy= M3fmSVLDqGh? M33Vc5Bz\X[nboTzJJRp\SCrbnPy[YF{\SCrbjDjcIVifmWmIN8xJJN2[nWwaYTzJJdp\W5iW17hL31qyqC5YYOgdoVlfWOnZB?= MXOyOVc3PzFzNR?=
HepG2  NF;nR2hHfW6ldHnvckBCe3OjeR?= NFHSV2Ey6oDLwsXNxsA> NX7BXFRFOjRiaB?= NV\S[lB6TE2VTx?= M3juUoRm[3KnYYPld{B1cGVibHX2[Ywhd2ZiUGjSJI1TVkF? MXeyOVYyPjV7Nx?=
SMCs MmjSSpVv[3Srb36gRZN{[Xl? NILud4wy|rypL33M NIHJc5Q{KGh? MmruZYNkfW23bHH0[ZMhS06SWUKgdJJwfGWrbjDpckB1cGViRWKgZ49ueGG{dH3lcpQh[W6mIH7vJIxwdmencjDjc{1td2OjbHn6[YQhf2m2aDD0bIUhT2:uZ3mgcYFzc2W{wrC= MYeyOVU5QTR{NR?=
OB-6 NXjnW442SXCxcITvd4l{KEG|c3H5 NYDaenZNOi55wrFOwG0> NETNeWY1QCCq NXXVO3dlcW6mdXPld{BieG:ydH;zbZM> MX2yOVU{OjR6MB?=
iPSC-CMs  NGHkOFNHfW6ldHnvckBCe3OjeR?= M3ryRlUxOCCwZz;tcC=> M37Y[|Q5KGh? NGrxUGdqdmO{ZXHz[ZMhfGinIHnueIVve2m2eTDv[kB1cGViaHnnbIVzKG2xYnnsbZR6KEyDTWDzJIF1KHSqZTDjc5N1KG:oIITo[UBtd3encjDtc4JqdGm2eTDzdIVkcWW| M4f3VlI2PDh6Nk[2
SP-Nluc MlG2SpVv[3Srb36gRZN{[Xl? Mn7EOUBu\y:vTB?= Ml3EOkBp MV3EUXNQyqB? M4rWVoNifXOnczDhckBqdmO{ZXHz[UBqdiC{ZYDvdpRmeiCjY4Tpeol1gSCrbjD0bIUheGG{YYPpeIU> M2LOOVI2Ozl{OUm4
PEXEL-Nluc NVfHOZY5TnWwY4Tpc44hSXO|YYm= NGH6N4I2KG2pL33M MnzFOkBp MnuzSG1UV8Li M3\CNoNifXOnczDhckBqdmO{ZXHz[UBqdiC{ZYDvdpRmeiCjY4Tpeol1gSCrbjD0bIUheGG{YYPpeIU> M{XxW|I2Ozl{OUm4
H1299 NU\WUGZMTnWwY4Tpc44hSXO|YYm= M2TLZlExKM7:Zz;tcC=> MX:yOEBp M37JUolv\HWlZYOgZZV1d3CqYXf5xsA> NX3hVlh3OjV|OEi5O|A>
MDA-MB-231 M1\wR2NmdGxiVnnhZoltcXS7IFHzd4F6 NH7xUZQx6oDVNUCg{txoN22O NVnEOlVRPDhiaB?= M1q2[WVEPTEEoE2gNE4xOTZiwsXnM41N MlOzNlU{PTZ3Nke=
MDA-MB-231 NEnXfWNCeG:ydH;zbZMhSXO|YYm= NXnWS5c1OC5zIN88[{9uVA>? NYjIRmNWPCCq NVTs[2Y{cW6mdXPld{BieG:ydH;zbZM> MUiyOVM2PjV4Nx?=
MDA-MB-231 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XhbVAvODFxMD6wOUDPxGdxbVy= M3HDeFI1KGh? MmrRbY5kemWjc3XzJJRp\SCocnHjeIlwdiCxZjDzeYIuTzFiY3XscEBl\WK{aYO= MnX4NlU{PTZ3Nke=
MDA-MB-231 MVHBdI9xfG:|aYOgRZN{[Xl? MmrsNE4xPeLCk{Gg{txoN22O M{HtT|I1KGh? MYLpcoR2[2W|IGDBVnAhMHCxbImgRWRRNXKrYn;z[UBxd2y7bXXyZZNmNTFrIHPs[YF3[Wen M37vflI2OzV4NU[3
MDA-MB-231 NIDNOIVHfW6ldHnvckBCe3OjeR?= M1rQNlDjiJN3MDFOwIcwdUx? M2TvdlI1KGh? NYnUbXgxcW6qaXLpeJMhfGinIH\vdo1ifGmxbjDv[kA{TCCjbnSgNmQh[2:ub37p[ZM> MlPrNlU{PTZ3Nke=
A172 MYnGeY5kfGmxbjDBd5NigQ>? MV6xNOKh|rypL33s NWn0cYV4PMLiaB?= MV\EUXNQyqB? NVPKVFZlemW|dXz0d{BqdiC2aHWgdoV1em:pcnHk[UB1emGwc4DvdpQhd2ZiZnz1c5Jme2OnboSg[5JidnWuZYO= NF2ybYQzPTJ|OUWwOy=>
KMS-6 NEK4e4xHfW6ldHnvckBCe3OjeR?= M4L5cVHDqM7:TdMg MVOyOEBp NVG3Rll2\XiqaXLpeJMhcGGuZjD0bIUhe2WlcnX0bY9vKG:oIHfhcIFvcW5vTFmgZZMh\GmmIITo[UBkd262cn;s M33Ic|I2OjJ7MUK2
MEC MoTrSpVv[3Srb36gRZN{[Xl? Mm\5NUDPxE1? NFSy[YkyNjViaB?= M3zyXoNifXOnczDhJIRz[W2jdHnjJIRm[3KnYYPlJIlvKHSqZTDzeZJn[WOnIG\FS2ZTOg>? MWmyOVIzQDhzNR?=
HEK293/hERG MmXzSpVv[3Srb36gRZN{[Xl? MWexNOKh|ryP MkDsNeKhcA>? M333b5Jme3WudIOgbY4h[SC2aX3lMYRmeGWwZHXueEBz\WS3Y4Tpc44hdWG2dYLlJIhGWkdicILveIVqdsLi NEDB[|QzPTJzOES2PS=>
RBE4 NY\OeIFHSXCxcITvd4l{KEG|c3H5 NXnnXlZROsLizszN NHH2T3E{6oDVMkVCpIg> NYO5WHQxcW6mdXPld{BieG:ydH;zbZMhfGmvZTDk[ZBmdmSnboTsfS=> NVvFOJJNOjVzMkiwNlU>
RBE4 MXTGeY5kfGmxbjDBd5NigQ>? M2KzV|LDqM7:TR?= MnrIN-KBmzJ2wrDo MXXpcoNz\WG|ZYOgeIhmKFiEUEGgdJJwfGWrbjDs[ZZmdHNiYX\0[ZIhOyCjbnSgOuKhcCCxZjD0doVifG2nboS= NETSVZQzPTF{OECyOS=>
RBE4 NIjqfXBHfW6ldHnvckBCe3OjeR?= M{HjU|LDqM7:TR?= NVTxdGRLO+LCk{K0xsBp MofSbY5kemWjc3XzJIFkfGm4ZTDjZZNx[XOnLUGyJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXyxsA> Ml75NlUyOjhyMkW=
RBE4 NHPhe3NHfW6ldHnvckBCe3OjeR?= MmjINuKh|ryP M4HQdVPjiJN{NNMgbC=> NWmxbnRocW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gVm9UKHSrbXWt[IVx\W6mZX70cJk> NHTuUpYzPTF{OECyOS=>
RBE4 NFywdXJHfW6ldHnvckBCe3OjeR?= MUmyxsDPxE1? MYKz5qCUOjUEoHi= NH\oRXZqdmS3Y3XzJIEh\GWuYYnl[EBl\XCuZYTpc44hd2ZidHjlJGVTKEOjMjxCpINwdnSnboSgZZQhPsLiaDDv[kBqdmO3YnH0bY9vKHOrZ37p[olk[W62bIm= NWLhdnVuOjVzMkiwNlU>
RBE4 Mnj5SpVv[3Srb36gRZN{[Xl? NHXyXFUzyqEQvF2= NGq2T20{6oDVMkVCpIg> NWDkPGFvcW6mdXPld{BidiCxdnXycI9i\CCxZjDDZVIsyqCrbjD0bIUhdWm2b3Poc45lemmjIHnuJJRp\SCoaYLzeEA3yqCqIH;mJIlv[3WkYYTpc44hMHEkgJm85qCKOC5yMEGpJIJ2fCCFYUKrxsBt\X[nbIOgbY4hfGirczDvdodidmWubHWg[IVkemWjc3XkJIFnfGW{IEGyxsBpKG:oIHnuZ5Vj[XSrb36= MXOyOVEzQDB{NR?=
Huh-7  M4PiPWZ2dmO2aX;uJGF{e2G7 MX6x{txoN22O M3fINlPjiJN{NNMgbC=> Mlz3bY5kemWjc3XzJJRp\SCuZY\lcEBw\iCDUFWxJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy MoLkNlUxOjZzN{S=
HepG2  MoTmSpVv[3Srb36gRZN{[Xl? M2rpTlHPxGdxbVy= NHfLdms{6oDVMkVCpIg> MkD4bY5kemWjc3XzJJRp\SCuZY\lcEBw\iCDUFWxJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy NXr3XFdCOjVyMk[xO|Q>
H838-LKB1 NWPxT|NwTnWwY4Tpc44hSXO|YYm= M3HqfVMxyqCwZz;tcC=> M1jkWFEzNzF6IHi= MoTBbY5kemWjc3XzJJRp\SCycn;0[YlvKGyndnXsd{Bw\iCEaWFCpC=> NXuwPWhvOjVyMUGwPFI>
H838-KDLKB1  NVnnfmJrTnWwY4Tpc44hSXO|YYm= NET6UFk{OMLibnevcYw> MXuxNk8yQCCq NEHQZXNqdmO{ZXHz[ZMhfGinIIDyc5RmcW5ibHX2[Yx{KG:oIFLpVOKh MlHINlUxOTFyOEK=
H838-KDLKB1  MkDNSpVv[3Srb36gRZN{[Xl? NX\6fJZ6OzEEoH7nM41t M{nsOlEzNzF6IHi= MYnpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyaH;zdIhwenmuYYTl[EBmUUZ{zsGgLJBpd3OyaH:t[WlHOs7zKR?= NGe0fI0zPTBzMUC4Ni=>
3T3-L1 NVjjfJlxTnWwY4Tpc44hSXO|YYm= NIi1ZYI2KM7:Zz;tcC=> NWD5[YpwOzBibXnu Ml24cYlucWO|IITo[UBm\m[nY4TzJI9nKGmwc4XsbY4h[W6mIHPheZNmeyC{b3L1d5QheGixc4Doc5J6dGG2aX;uJI9nKEGtdDCoV4VzKDR5MzmgZY5lKHCqb4PwbI9zgWyjdHnvckBw\iCDU{G2NEApXGi{IE[0NkBidmRiU3XyJFU5QCl? MYSyOFg1Ozh{Nx?=
3T3-L1 M4\sZWZ2dmO2aX;uJGF{e2G7 NGnGOpU2KM7:Zz;tcC=> M3L1VFMxKG2rbh?= M3H5b5Jm[2GyaYT1cIF1\XNiaX7zeYxqdiCjY4Tpc44hf2m2aDDy[ZNx\WO2IITvJJJm\3WuYYTpcochSWu2IHHjeIl3cXS7IHHu[EBCWzF4MDDwbI9{eGixconsZZRqd25? NXLtTFdFOjR6NEO4Nlc>
3T3-L1 NVO5TJZ2TnWwY4Tpc44hSXO|YYm= M33GOFUh|rypL33s NEX2N5U{OCCvaX6= NHnPbpdk[XW|ZYOgdoV3\XK|aXLs[UBz\WSrc4TybYJ2fGmxbjDv[kBIVFWWNB?= MnTiNlQ5PDN6Mke=
3T3-L1 NV[5VFRDTnWwY4Tpc44hSXO|YYm= M{DYe|Uh|rypL33s MkCyNeKhcA>? Mn[zZ4F2e2W|IILl[Il{fHKrYoX0bY9vKG:oIFfMWXQ1KGK3dDDuc5QhcW6lcnXhd4UhcW5iZ3z1Z49{\SC3cIThb4U> NE\BWmkzPDh2M{iyOy=>
3T3-L1 NFTvO2ZHfW6ldHnvckBCe3OjeR?= NEjpdWk2KM7:Zz;tcC=> MknNNeKhcA>? MWDjZZV{\XNicHjvd5Bpd3K7bHH0bY9vKG:oIITo[UBHd3iRMTD0doFve2O{aYD0bY9vKG[jY4Tvdi=> M2PTR|I1QDR|OEK3
HeLa  M1focGZ2dmO2aX;uJGF{e2G7 M{ThblUh|rypL33s M3zEcVMhcA>? MoLtZ4F2e2W|IH71Z4xm[XJiZYjjcJV{cW:wIH;mJJRp\SCIb4jPNUB1emGwc3PybZB1cW:wIH\hZ5RweiCjbnSg[IVkemWjc3XzJJRz[W6|Y4LpdJRqd25ib3[gSo95VzFvcnXneYxifGWmIHflcoV{ NYLGVpR[OjR6NEO4Nlc>
HEK293 MkK2SpVv[3Srb36gRZN{[Xl? NXWxV2o6PcLizsznM41t MWCxNuKhcA>? NHnT[5Zi[m:uaYPo[ZMhS02DLXnu[JVk\WRiQ2LFUGQzKHOnY4LleIlwdg>? NIrNOI0zPDZ6N{SzNS=>
COS-1 M4PPV2Z2dmO2aX;uJGF{e2G7 NEfR[XM2KML3Zz;tcC=> NFjO[5MzPCCqwrC= MkjndoV{fHKrY4TzJIxw[2GuaYrheIlwdiCxZjDORkBqdiC2aHWgdIVzcW63Y3zlZZIhemWpaX;uxsA> MYGyOFY4OTd3MR?=
PRP NFvPSoNHfW6ldHnvckBCe3OjeR?= MVKxNEDPxE1? M4nR[oFjem:pYYTld{BUTEZvMd8xMY1m\GmjdHXkJGNZS1J5IHX4eIVzdmGuaYrheIlwdsLi NWT1b|JUOjR4Nki3OVA>
RAW264.7 NHLrb25CeG:ydH;zbZMhSXO|YYm= MWW0JO69VQ>? MUO0PEBp M3;0XIF1fGWwdXH0[ZMhfGinIHnubIljcXSrb36gc4Yhd3hvTFTMMYlv\HWlZXSgZZBweHSxc3nzJIFv\CC2aHWg[oFkcWyrdHH0bY9vKG:oIHPoc4xme3Sncn;sJIVn\my3eDDifUBC[y2qRT2xPGEuVkh{ NF\he4wzPDZ|OUCzNi=>
MDMs M1TmSmFxd3C2b4Ppd{BCe3OjeR?= Mn20NVDjiIoQvHevcYw> NYjwNZZXOTJxMUWgbC=> MlTSbY5lfWOnczDhdI9xfG:|aYO= NXP6e5VSOjR3NU[2PVU>
PMHs  NGjvXXRHfW6ldHnvckBCe3OjeR?= NHvLXZIyOOLCk{Kw5qCK|rypL33s M2H2b|I16oDLaB?= M2LvWWROW09? NUnKV5dCcW6mdXPl[EBGWiC|dILld5M> M3j2TFI1PDB5MkSy
PMHs  Ml;pRZBweHSxc3nzJGF{e2G7 MnHWNVDjiJN{MPMAje69\y:vbB?= MX[yOQKBkWh? NX3uOWxSTE2VTx?= NWrVVo9HcW6lcnXhd4V{KGOnbHyg[IVifGh? NWH4THFFOjR2MEeyOFI>
HEK293/tau M1:3W2Z2dmO2aX;uJGF{e2G7 M{TGRlUh|ryP MmjKNU8zNzRiaB?= MlnxbY5lfWOnczDHc4xocSCocnHncYVvfGG2aX;uxsA> M{f6eFI1OzZ6MEi5
HEK293/tau MWnGeY5kfGmxbjDBd5NigQ>? MX21JO69VQ>? MlewN{Bp NVrCRo16cW6mdXPld{B1[XViaInw[ZJxcG:|cHjvdplt[XSrb36= MojyNlQ{PjhyOEm=
ADF NX76SVlXTnWwY4Tpc44hSXO|YYm= M{e1cVExKM7:TR?= NX\2dmZvOTZiaB?= MkOwbY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> NVvmOFN[OjR{MkiyN|I>
U373  NXrDfm1WTnWwY4Tpc44hSXO|YYm= M2HQ[|ExKM7:TR?= NEjrXmsyPiCq NXq3RnJjcW6qaXLpeJMhfGinIGruR4wzNWmwZIXj[YQhfHKjboPsc4NifGmxbjDv[kBEWlR? NYXHT49jOjR{MkiyN|I>
RKO-HIPK2i M4fUUWZ2dmO2aX;uJGF{e2G7 Mn[wNVAh|ryP NX;MWVFHOTZiaB?= NH3HS|hqdmirYnn0d{B1cGViWn7DcFIucW6mdXPl[EB1emGwc3zvZ4F1cW:wIH;mJGNTXA>? M1;SbVI1OjJ6MkOy
ADF  NIL5TGZHfW6ldHnvckBCe3OjeR?= M3PYVFExKM7:TdMg Mm\FOkBp M1LVU4lueGGrcoOgeIhmKESFIHHjeIl3[XSrb36= NH;SbFczPDJ{OEKzNi=>
Huh7 NV7xPZdxTnWwY4Tpc44hSXO|YYm= MlHXOUDPxGdxbXy= NUPQd|N1PCCq MYfhZo9tcXOqZYOgeIhmKHOnY4LleIlwdiCxZjCgbY51emGlZXzseYxieiCDcH;C NIrKS3EzPDFyMEG0NC=>
Huh7 NHW3[2hHfW6ldHnvckBCe3OjeR?= MV61JO69\y:vbB?= MlfpNUBp MYrjZZV{\XNiYTDzbYdvcW[rY3HueEBqdmO{ZXHz[UBqdiCDcH;CMYNz\XOlZX70dy=> M1iwRlI1OTByMUSw
Huh7 MVPGeY5kfGmxbjDBd5NigQ>? MmDWOgKBmzFywrDu[{9udA>? M{n1SlEzKGh? MWXpcoNz\WG|ZYOgRZBwSi2lcnXzZ4VvfHNid3n0bI92fCCrbnjpZol1cW6pIIPlZ5JmfGmxbh?= M1\I[FI1OTByMUSw
BAECs M1LYb2Z2dmO2aX;uJGF{e2G7 M2PmPFUh|rypL33s NYPuUIFYOC12IHi= NYDGVmFCcW6mdXPld{B1cGVicnHwbYQh\GWyaH;zdIhwenmuYYTpc44hd2ZiZV7PV{BifCCVZYKxNVc6 NX3NWo9JOjRyOEWyNlU>
Macrophages NEDH[oFHfW6ldHnvckBCe3OjeR?= NUTidmM5PzFiwsXN MYe2JIg> MYnpcohq[mm2czDseY5ie2mwIHnueIVzdmGuaYrheIlwdsLi NXfEfIFTOjRyM{m3OFA>
Colo 205 NUjHZlN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Xr[lAuPSEQvHevcWw> NWrmdIh1PDhiaB?= NVPm[4hOcW6qaXLpeJMh[2WubDDndo94fGhiaX6gd5V{eGWwc3nvckBkfWy2dYLld{B4cXSqIHHuJIV{fGmvYYTl[EBKSzVyIH;mJJ4yPSCwZz;tUC=> MYKyN|k4Ozl7Nh?=
Colo 205 NXzy[HQ1TnWwY4Tpc44hSXO|YYm= M{ftSVAvODF{LUCuNFI2KM7:Zz;tUC=> Mli3NVQh\A>? NUPTcIY5emWmdXPld{B1cGViY3zvco9o\W6rY3n0fUBw\iCFb3zvJFIxPSCFU1Pz NFe3SVYzOzl5M{m5Oi=>
Colo 205 NVPVT|FMSXCxcITvd4l{KEG|c3H5 M4nwUVAvOSEQvHevcWw> M1LLT|AuOjRiaB?= MUDpcoR2[2W|IHHwc5B1d3OrczDv[kBEd2yxIEKwOUBk\WyuczDpckB{fXOyZX7zbY9vKGO3bIT1doV{ NVH2PZVXOjN7N{O5PVY>
Colo 205 M3e3bWZ2dmO2aX;uJGF{e2G7 NEmxNpIxNjBzNTFOwIcwdUx? M{PCR|I1KGh? MYPpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFXSJJN1emW|cz3y[YxifGWmIHflcoV{ NV;y[lVROjN7N{O5PVY>
Colo 205 NE\kdZNHfW6ldHnvckBCe3OjeR?= NHTL[osxNjBzNTFOwIcwdUx? NGrnbVIzPCCq NHj5ZYxqdmirYnn0d{B1cGViYXP0bZZqfHlib3[gUW1Rew>? M3LyRlI{QTd|OUm2
IBRS2 Mn\RSpVv[3Srb36gRZN{[Xl? NUm0dYV5PSEQvHevcYw> MYCwMlUhcA>? NWHRSXlTTE2VTx?= MXfkbZNzfXC2czD0bIUhTVKJSVOgZY5lKEexbHfpxsA> MUiyN|k3OzV|NB?=
IBRS2 MULGeY5kfGmxbjDBd5NigQ>? MoD6OUDPxGdxbXy= MWmwMlUhcA>? M3XDdGROW09? MWXlcohidmOnczDGUWRXKGmwZnXjeIlwdg>? MW[yN|k3OzV|NB?=
HeLa MV\GeY5kfGmxbjDBd5NigQ>? MUWyJO69VQ>? M2LqclIhcMLi M{fZToF1fGWwdXH0[ZMhfGinIGTOSk1qdmS3Y3XkJJNm[3KndHnvckBw\iCLTD2xOS=> NGfsSGIzOzl3MEi5Ni=>
HFS  MoDXSpVv[3Srb36gRZN{[Xl? NYm5VHVXOC1zIN88[{9udA>? Mmr1NlQhcA>? NV:wWYJDT0yWUDDlfJBz\XO|aX;uJJJm[WOqZYOgZUBxdGG2ZXH1JIF1KGOxbnPlcpRz[XSrb37zJIF{KGyxdzDhd{AxNjBzINM1[{9udA>? NWPxOVF4OjN6OUS2N|M>
HFS  NHP3OJVHfW6ldHnvckBCe3OjeR?= M1;YSlAvODFiwsXnM41t NFfWPGQzPCCq NWP2R4ZqcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGeueXPvd5BpcW6pb3zpdIllKHO7boToZZNmKGenbnXzJIF1KDZiaB?= NITNRVEzOzh7NE[zNy=>
OVCAR-3 MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf1O4FyOeLCk{G1xsDPxE4EoB?= M{W2cVI1yqCq MkDPbY5lfWOnczDhJIxwe3Nib3[gZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgcLi NVvGXG1ROjN6Mk[5OlQ>
OVCAR-3 MWfGeY5kfGmxbjDBd5NigQ>? NEXleHQy6oDVMUZCpO69VcLi Mn25NlTDqGh? NIP3blZqdmS3Y3XzJI52[2ynYYKg[IFu[Wen NFm0eFIzOzh{Nkm2OC=>
OVCAR-3 MmHQRZBweHSxc3nzJGF{e2G7 MWCxMVExyqEQvF2= NHvCWZo1KGh? MXHpcoR2[2W|IITo[UBi[3SrdnH0bY9vKG:oIHHwc5B1d3Orcz3y[YxifGWmIIDyc5RmcW6| MmTpNlM5OjZ7NkS=
OVCAR-3 NHnQTFJCeG:ydH;zbZMhSXO|YYm= MXixNOKh|ryP M13Qe|I1yqCq NEDFTIRqdmS3Y3XzJIFkfGm4YYTpc44hd2ZiY3HzdIF{\XN? MlnzNlM5OjZ7NkS=
OVCAR-3 NGTFSm1HfW6ldHnvckBCe3OjeR?= NETkPGIy6oDVMUFCpO69VQ>? MWGyOOKhcA>? M4D3PIlv\HWlZYOg[Il{enWydHnvckBw\iC2aHWgcYl1d2Oqb37kdolidCC2cnHud41mdWK{YX7lJJBwfGWwdHnhcC=> MoH5NlM5OjZ7NkS=
OVCAR-3 MnTESpVv[3Srb36gRZN{[Xl? NFzEOmoy6oDVMUFCpO69VQ>? NFjmc|kzPMLiaB?= M1vWXIlv\HWlZYOg[o9zdWG2aX;uJI9nKHKnYXP0bZZmKG:6eXflckB{eGWlaXXz NULKPXVzOjN6Mk[5OlQ>
OVCAR-3 M2HxV2Z2dmO2aX;uJGF{e2G7 M3H3TFHjiJNzMNMg{txO NWnHbYdoOjUEoHi= MVfpcohq[mm2czDj[YxtKGGmaHXzbY9vKGGwZDDtbYdz[XSrb36= NX3ldos4OjN6Mk[5OlQ>
MKN45 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfGcHRNUUN3MEywMlAxOSEQvHevcYw> MY[yN|c6OzN2Mh?=
LOVO M2HUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTiPYpKSzVyPUCuNVIh|rypL33s M{DHSVI{Pzl|M{Sy
A549 NUfxRmVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMESg{txoN22u MW[yN|c6OzN2Mh?=
MDA-MB-435 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrjTWM2ODxyLkCwNUDPxGdxbXy= MUeyN|c6OzN2Mh?=
HepG2 M4DZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzPRZN2UUN3MEywMlAxOSEQvHevcYw> MYqyN|c6OzN2Mh?=
HL-60 MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm1WHVKSzVyPECuNFAyKM7:Zz;tcC=> MnLENlM4QTN|NEK=

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:

[5]

+ Expand
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method:

    HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products0

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID